Table 1.
Different approved COVID-19 vaccines.
| Sl. No. | Approved COVID-19 Vaccines | Developer of the Vaccines | Vaccine Type/Platform | Country of Origin | Storage Temperature (°C) | Dose | Reference |
|---|---|---|---|---|---|---|---|
| 1. | Pfizer–BioNTech vaccine | BioNTech SE, Pfizer Inc. | Nucleoside-modified mRNA | Germany, USA | −70 ± 10 | Two doses given three weeks apart | [38] |
| 2. | Moderna vaccine (mRNA-1273) |
United States National Institute of Allergy and Infectious Diseases, Moderna Inc., Biomedical Advanced Research and Development Authority, Coalition for Epidemic Preparedness Innovations |
Nucleoside-modified mRNA | USA | −20 ± 5 | Two doses given four weeks apart | [39] |
| 3. | Oxford–AstraZeneca vaccine | AstraZeneca plc, University of Oxford, Coalition for Epidemic Preparedness Innovations |
Modified adenovirus vector | Sweden, UK | 2–8 | Two doses given four to twelve weeks apart | [40] |
| 4. | Sputnik V | Gamaleya Research Institute of Epidemiology and Microbiology | Modified adenovirus vector | Russia | ≤−18 | Two doses given three weeks apart | [41] |
| 5. | Johnson & Johnson vaccine | Janssen Pharmaceuticals, Beth Israel Deaconess Medical Center |
Modified adenovirus vector | Belgium, Netherlands |
2–8 | One dose | [42] |
| 6. | Ad5-nCoV | CanSino Biologics, Beijing Institute of Biotechnology |
Modified adenovirus vector | China | 2–8 | One dose | [43] |
| 7. | BBIBP-CorV | Beijing Institute of Biological Products, Wuhan Institute of Biological Products, China National Pharmaceutical Group Corporation |
Inactivated SARS-CoV-2 | China | 2–8 | Two doses given three to four weeks apart | [44] |
| 8. | ZF2001 | Chinese Academy of Sciences, Anhui ZhifeiLongcom Biologic Pharmacy Co., Ltd. |
Adjuvanted protein subunit | China | - | Three doses given in thirty days apart | [45] |
| 9. | CoronaVac | Sinovac Biotech Ltd. | Inactivated SARS-CoV-2 | China | 2–8 | Two doses given two weeks apart | [46] |
| 10. | BBV152 | Bharat Biotech International Limited, Indian Council of Medical Research |
Inactivated SARS-CoV-2 | India | 2–8 | Two doses given four weeks apart | [47] |
| 11. | EpiVacCorona | State Research Centerof Virology and Biotechnology VECTOR | Peptide subunit | Russia | 2–8 | Two doses given three to four weeks apart | [48] |
| 12. | CoviVac | Russian Academy of Sciences | Inactivated SARS-CoV-2 | Russia | 2–8 | Two doses given two weeks apart | [49] |